Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERPENTINE: Durvalumab +/- Tremelimumab in Colorectal and Endometrial Tumors
NCT06680739Phase 2Recruiting
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Mar 2022
- Primary completion
- Jul 2032
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab and tremelimumab in colorectal cancer (CRC) and endometrial cancer (EC) (3 arms), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoint: Objective Response Rate at 24 months. Started Mar 2022; status: recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
colorectal cancer (CRC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06680739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680739.